Antibody-Drug Conjugate - ADC

ADC (Antibody-drug conjugate) is a next-generation antibody-drug conjugate that has improved efficacy over existing antibodies. This drug combines the advantages of two factors: target specificity, which is a characteristic of an antibody, and cytotoxicity, which is a characteristic of a drug. Specifically, this is a technology focused on targeting and killing cancer cells by delivering drugs that cause cytotoxicity to tumor cells using antibodies that can bind to cancer cell-specific antigens. The Artificial Intelligence algorithm developed by Deargen can derive candidate substances that can control the target protein by predicting the affinity between the target protein and the drug. It is expected that the binding of the substance discovered through the AI solution to the tumor cell-specific antibody will provide more improved therapeutic effect compared to single agent treatment.